This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ReNeuron Group Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.7yrs
Board average tenure	1.7yrs

Recent management updates

Recent updates

CEO

ReNeuron Group has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Iain Ross	Executive Chairman	2.8yrs	UK£430.00k	0.70% £ 13.5k
John Hawkins	Company Secretary	2.9yrs	UK£192.91k	0.26% £ 5.0k
John Sinden	Co-Founder	no data	UK£221.00k	no data
Suzanne Hancock	Chief Operations Officer	3.8yrs	no data	0.074% £ 1.4k
Randolph Corteling	Chief Scientific Officer	1.7yrs	no data	no data
Simon Dew	Chief Business Officer	1.5yrs	no data	no data

1.7yrs

Average Tenure

69yo

Average Age

Experienced Management: RENE's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Iain Ross	Executive Chairman	2.8yrs	UK£430.00k	0.70% £ 13.5k
John Hawkins	Company Secretary	1.7yrs	UK£192.91k	0.26% £ 5.0k
Martin Walton	Independent Non-Executive Director	2.2yrs	UK£50.00k	0.026% £ 506.3
Barbara Staehelin	Senior Independent Non-Executive Director	2.8yrs	UK£60.00k	0.61% £ 11.8k
Michael Owen	Independent Non-Executive Director	8.4yrs	UK£48.00k	0.020% £ 384.0
Stefano Pluchino	Chair of the Scientific Advisory Board	1.7yrs	no data	no data
Giuseppe Battaglia	Member of Scientific Advisory Board	1.1yrs	no data	no data
Edit Buzas	Member of Scientific Advisory Board	1.1yrs	no data	no data
Bernd Giebel	Member of Scientific Advisory Board	1.1yrs	no data	no data
Kenneth Witwer	Member of Scientific Advisory Board	1.1yrs	no data	no data

1.7yrs

Average Tenure

60yo

Average Age

Experienced Board: RENE's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.

This company listing is no longer active

ReNeuron Group Management

Management criteria checks 0/4

Key information

Recent management updates

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc, Annual General Meeting, Aug 22, 2023

High number of new and inexperienced directors

ReNeuron Group plc Appoints Iain Ross as Executive Chairman

Less than half of directors are independent

Less than half of directors are independent

Recent updates

ReNeuron Group Admission to Trading on AIM to Be Cancelled with Effect from 2 September 2024

ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024

ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024

Consensus revenue estimates decrease by 28%, EPS upgraded

New minor risk - Profitability

ReNeuron Group plc to Report First Half, 2024 Results on Nov 09, 2023

ReNeuron Group plc, Annual General Meeting, Aug 22, 2023

Consensus EPS estimates upgraded to UK£0.10 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

ReNeuron Group plc to Report Q4, 2023 Results on May 25, 2023

High number of new and inexperienced directors

ReNeuron Group plc Appoints Iain Ross as Executive Chairman

Consensus forecasts updated

First half 2023 earnings released: UK£0.056 loss per share (vs UK£0.092 loss in 1H 2022)

No longer forecast to breakeven

Less than half of directors are independent

Less than half of directors are independent

ReNeuron Group plc Appoints John Hawkins as Chief Financial Officer

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc, Annual General Meeting, Sep 09, 2022

ReNeuron Group plc Announces Appointment of Catherine Isted as Chief Executive Officer, Effective 1 September 2022

We Think ReNeuron Group (LON:RENE) Needs To Drive Business Growth Carefully

Price target decreased to UK£2.22

Full year 2022 earnings released: UK£0.17 loss per share (vs UK£0.29 loss in FY 2021)

ReNeuron Group plc to Report Fiscal Year 2022 Results on Jul 04, 2022

Price target decreased to UK£2.19

ReNeuron Group plc, Annual General Meeting, Jul 14, 2022

Price target decreased to UK£2.04

ReNeuron Group plc Announces CEO Changes, Effective 28 February 2022

ReNeuron Group plc Announces Leaving of Olav Hellebø as Executive Director

We're Keeping An Eye On ReNeuron Group's (LON:RENE) Cash Burn Rate

Price target decreased to UK£2.04

First half 2022 earnings: EPS and revenues miss analyst expectations

Companies Like ReNeuron Group (LON:RENE) Can Afford To Invest In Growth

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Full year 2021 earnings released: UK£0.29 loss per share (vs UK£0.36 loss in FY 2020)

Will ReNeuron Group (LON:RENE) Spend Its Cash Wisely?

ReNeuron Group plc Announces Resignation of Michael Hunt, Chief Financial Officer

Is ReNeuron Group (LON:RENE) In A Good Position To Deliver On Growth Plans?

New 90-day high: UK£1.11

New 90-day low: UK£0.72

First half 2021 earnings released: UK£0.22 loss per share

New 90-day low: UK£0.78

Here's What We Learned About The CEO Pay At ReNeuron Group plc (LON:RENE)

ReNeuron Group plc to Report First Half, 2021 Results on Nov 10, 2020

New 90-day low: UK£0.85

Analysts update estimates

ReNeuron Group plc Auditor Raises 'Going Concern' Doubt

Full year earnings released - UK£0.36 loss per share

New 90-day low - UK£1.08

New 90-day low - UK£1.22

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age